VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

SOHO 2018 | CAR-T therapy as a replacement for triple combination therapy in CLL

From the 2018 Society of Hematologic Oncology (SOHO) in Houston, TX, Barbara Eichhorst from the University Hospital Cologne, Cologne, Germany, discusses ongoing trials investigating CAR T-cell therapy in patients with chronic lymphocytic leukemia (CLL). Due to a defect in the patients’ T-cells, there was less success for in the beginning of CAR T-cell treatment. Recent results from trials however, show that when administering the BTK inhibitor ibrutinib beforehand, CAR T-cell retransfusion becomes more successful. Results of better tolerance of neurotoxicity and cytokine release syndrome show promising potential for CAR T-cells. Prof. Eichhorst talks about the future of treatment of CLL, highlighting the potential replacement of triple combination therapy, where a continuous treatment of obinutuzumab, ibrutinib, and venetoclax is used, with CAR T-cells therapy.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter